Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression

Abstract EN

Aripiprazole is the first medication approved by the FDA as an add-on treatment for MDD.

The impact of aripiprazole on the response to HIV is unknown.

The patient we report on was diagnosed HIV-positive in 1997 and has been treated with antiretroviral therapy since then.

In 2008, we diagnosed resistant major depression, hypochondria, and panic disorder.

On that occasion, blood tests showed a significantly reduced CD4 count and a positive viral load.

We treated this patient with aripiprazole and citalopram.

Mood, somatic symptoms, and occupational functioning progressively improved.

The last blood examination showed an increase in the CD4 count and a negative viral load.

On the basis of the present case study and the review of the literature concerning the effects of psychotropic agents on viral replication, we suggest that the use of aripiprazole in HIV-infected subjects warrants further research.